Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The production of human induced pluripotent stem cells (hiPSCs) has greatly expanded the realm of possible stem cell-based regenerative medicine therapies and has particularly exciting potential for autologous therapies. However, future therapies based on hiPSCs will first have to address not only similar regulatory issues as those facing human embryonic stem cells with the US FDA and international regulatory agencies, but also hiPSCs have raised unique concerns as well. While the first possible clinical use of hiPSCs remains down the road, as a field it would be wise for us to anticipate potential roadblocks and begin formulating solutions. In this article, I discuss the potential regulatory issues facing hiPSCs and propose some potential changes in the direction of the field in response. Original submitted 20 April 2012; Revised submitted 25 May 2012; Published online 26 July 201.

Original languageEnglish (US)
Pages (from-to)713-720
Number of pages8
JournalRegenerative Medicine
Volume7
Issue number5
DOIs
StatePublished - Sep 2012

Fingerprint

Induced Pluripotent Stem Cells
Stem cells
International Agencies
Regenerative Medicine
Stem Cells
Therapeutics

Keywords

  • FDA
  • hiPSC
  • induced pluripotent stem cell
  • iPS cell
  • stem cell
  • translational medicine

ASJC Scopus subject areas

  • Biomedical Engineering
  • Embryology

Cite this

Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells. / Knoepfler, Paul S.

In: Regenerative Medicine, Vol. 7, No. 5, 09.2012, p. 713-720.

Research output: Contribution to journalArticle

@article{1466cc1e3fcb47e8a46788b023d1c6d1,
title = "Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells",
abstract = "The production of human induced pluripotent stem cells (hiPSCs) has greatly expanded the realm of possible stem cell-based regenerative medicine therapies and has particularly exciting potential for autologous therapies. However, future therapies based on hiPSCs will first have to address not only similar regulatory issues as those facing human embryonic stem cells with the US FDA and international regulatory agencies, but also hiPSCs have raised unique concerns as well. While the first possible clinical use of hiPSCs remains down the road, as a field it would be wise for us to anticipate potential roadblocks and begin formulating solutions. In this article, I discuss the potential regulatory issues facing hiPSCs and propose some potential changes in the direction of the field in response. Original submitted 20 April 2012; Revised submitted 25 May 2012; Published online 26 July 201.",
keywords = "FDA, hiPSC, induced pluripotent stem cell, iPS cell, stem cell, translational medicine",
author = "Knoepfler, {Paul S}",
year = "2012",
month = "9",
doi = "10.2217/rme.12.51",
language = "English (US)",
volume = "7",
pages = "713--720",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Key anticipated regulatory issues for clinical use of human induced pluripotent stem cells

AU - Knoepfler, Paul S

PY - 2012/9

Y1 - 2012/9

N2 - The production of human induced pluripotent stem cells (hiPSCs) has greatly expanded the realm of possible stem cell-based regenerative medicine therapies and has particularly exciting potential for autologous therapies. However, future therapies based on hiPSCs will first have to address not only similar regulatory issues as those facing human embryonic stem cells with the US FDA and international regulatory agencies, but also hiPSCs have raised unique concerns as well. While the first possible clinical use of hiPSCs remains down the road, as a field it would be wise for us to anticipate potential roadblocks and begin formulating solutions. In this article, I discuss the potential regulatory issues facing hiPSCs and propose some potential changes in the direction of the field in response. Original submitted 20 April 2012; Revised submitted 25 May 2012; Published online 26 July 201.

AB - The production of human induced pluripotent stem cells (hiPSCs) has greatly expanded the realm of possible stem cell-based regenerative medicine therapies and has particularly exciting potential for autologous therapies. However, future therapies based on hiPSCs will first have to address not only similar regulatory issues as those facing human embryonic stem cells with the US FDA and international regulatory agencies, but also hiPSCs have raised unique concerns as well. While the first possible clinical use of hiPSCs remains down the road, as a field it would be wise for us to anticipate potential roadblocks and begin formulating solutions. In this article, I discuss the potential regulatory issues facing hiPSCs and propose some potential changes in the direction of the field in response. Original submitted 20 April 2012; Revised submitted 25 May 2012; Published online 26 July 201.

KW - FDA

KW - hiPSC

KW - induced pluripotent stem cell

KW - iPS cell

KW - stem cell

KW - translational medicine

UR - http://www.scopus.com/inward/record.url?scp=84866141793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866141793&partnerID=8YFLogxK

U2 - 10.2217/rme.12.51

DO - 10.2217/rme.12.51

M3 - Article

C2 - 22830621

AN - SCOPUS:84866141793

VL - 7

SP - 713

EP - 720

JO - Regenerative Medicine

JF - Regenerative Medicine

SN - 1746-0751

IS - 5

ER -